Similar articles

• The treatment of hormone refractory prostate cancer.

  Panvichian R, Pienta KJ. Panvichian R, et al. Compr Ther. 1996 Feb;22(2):81-7. Compr Ther. 1996. PMID: 8689867 Review. No abstract available.
• A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.

  [No authors listed] [No authors listed] Cancer Treat Res. 1992;59:29-40. Cancer Treat Res. 1992. PMID: 1347692 Clinical Trial. No abstract available.
• Prostatic cancer--what to do? Staging and prognostic factors in the primary therapy decision.

  Faul P. Faul P. Eur Urol. 1992;22(2):89-98. Eur Urol. 1992. PMID: 1478236 Review. No abstract available.
• [What is safe in the therapy of advanced prostatic cancer?].

  Gropp C, Burk K. Gropp C, et al. Internist (Berl). 1985 Dec;26(12):765-70. Internist (Berl). 1985. PMID: 3936819 German. No abstract available.
• Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.

  Rapkiewicz A, Gorokhovsky R, Farcon E, Das K. Rapkiewicz A, et al. Diagn Cytopathol. 2008 Jul;36(7):499-502. doi: 10.1002/dc.20814. Diagn Cytopathol. 2008. PMID: 18528888